Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
about
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityAdvances in the monitoring of anti-P2Y12 therapy.The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.
P2860
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y
@nl
Modification of the VerifyNow® ...... levels of P2Y(12) antagonism.
@en
type
label
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y
@nl
Modification of the VerifyNow® ...... levels of P2Y(12) antagonism.
@en
prefLabel
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y
@nl
Modification of the VerifyNow® ...... levels of P2Y(12) antagonism.
@en
P2093
P2860
P1433
P1476
Modification of the VerifyNow® ...... levels of P2Y(12) antagonism.
@en
P2093
Atsuhiro Sugidachi
Blaine Egan
Chunmei Zhou
Jeffrey R Dahlen
Joseph A Jakubowski
Maggie Wells
Maya Kotob-Yahfoufi
P2860
P304
P356
10.3109/09537104.2011.579203
P577
2011-06-06T00:00:00Z